Myriad Genetics Inc (MYGN)

Operating return on assets (Operating ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Operating income (ttm)	US$ in thousands	-101,700	-115,800	-155,900	-233,100	-257,400	-272,000	-256,900	-161,000	-123,700	-120,800	-155,700	-158,700	-190,500	-195,600	-155,300	-202,800	-289,800	-250,400	-231,700	-169,000
Total assets	US$ in thousands	1,027,600	1,081,300	1,085,100	1,110,500	1,146,500	1,149,100	1,187,200	1,169,300	1,198,700	1,212,000	1,210,200	1,255,400	1,320,700	1,335,900	1,360,300	1,336,900	1,418,800	1,444,500	1,404,600	1,446,700
Operating ROA		-9.90%	-10.71%	-14.37%	-20.99%	-22.45%	-23.67%	-21.64%	-13.77%	-10.32%	-9.97%	-12.87%	-12.64%	-14.42%	-14.64%	-11.42%	-15.17%	-20.43%	-17.33%	-16.50%	-11.68%

December 31, 2024 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $-101,700K ÷ $1,027,600K
= -9.90%

Myriad Genetics Inc's operating return on assets (operating ROA) has shown fluctuating performance over the periods analyzed. The data reveals a downward trend in the operating ROA from March 31, 2020, to December 31, 2024. The values ranged from -11.68% to -9.90% during this period.

The negative values indicate that Myriad Genetics Inc's operating income generated from its assets was insufficient to cover the cost of those assets. This suggests operating inefficiencies or lower profitability relative to the size of its asset base.

The company experienced its lowest operating ROA of -23.67% on September 30, 2023, indicating significant challenges in generating profits from its assets during that period. Subsequently, there was some improvement, as the operating ROA reduced to -9.90% by December 31, 2024.

Overall, the declining trend in operating ROA suggests potential inefficiencies in asset utilization or operational performance. It may be beneficial for Myriad Genetics Inc to focus on improving operational efficiency, optimizing asset utilization, and enhancing profitability to reverse this trend and strengthen its financial performance.